Modeling amantadine treatment of influenza A virus in vitro.

We analyzed the dynamics of an influenza A/Albany/1/98 (H3N2) viral infection, using a set of mathematical models highlighting the differences between in vivo and in vitro infection. For example, we found that including virion loss due to cell entry was critical for the in vitro model but not for the in vivo model. Experiments were performed on influenza virus-infected MDCK cells in vitro inside a hollow-fiber (HF) system, which was used to continuously deliver the drug amantadine. The HF system captures the dynamics of an influenza infection, and is a controlled environment for producing experimental data which lend themselves well to mathematical modeling. The parameter estimates obtained from fitting our mathematical models to the HF experimental data are consistent with those obtained earlier for a primary infection in a human model. We found that influenza A/Albany/1/98 (H3N2) virions under normal experimental conditions at 37 degrees C rapidly lose infectivity with a half-life of approximately 6.6+/-0.2 h, and that the lifespan of productively infected MDCK cells is approximately 13 h. Finally, using our models we estimated that the maximum efficacy of amantadine in blocking viral infection is approximately 74%, and showed that this low maximum efficacy is likely due to the rapid development of drug resistance.

[1]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[2]  G. Boivin,et al.  Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations , 2005, Antimicrobial Agents and Chemotherapy.

[3]  J A Bilello,et al.  Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies , 1994, Antimicrobial Agents and Chemotherapy.

[4]  D. Smee,et al.  In vitro and in vivo assay systems for study of influenza virus inhibitors. , 2000, Antiviral research.

[5]  F. Hayden Writing Committee of the Second World Health Organization (WHO) Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus , 2007 .

[6]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[7]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[8]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[9]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[10]  J. Chou,et al.  Structure and mechanism of the M2 proton channel of influenza A virus , 2008, Nature.

[11]  H. Oshitani,et al.  Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2 , 2003, Journal of Clinical Microbiology.

[12]  G. Bocharov,et al.  Mathematical model of antiviral immune response. III. Influenza A virus infection. , 1994, Journal of theoretical biology.

[13]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[14]  Vikas Nanda,et al.  Structural basis for the function and inhibition of an influenza virus proton channel , 2008, Nature.

[15]  Udo Reichl,et al.  Mathematical model of influenza A virus production in large-scale microcarrier culture. , 2005, Biotechnology and bioengineering.

[16]  R. Lamb,et al.  Influenza A Virus M2 Ion Channel Activity Is Essential for Efficient Replication in Tissue Culture , 2002, Journal of Virology.

[17]  A. Perelson,et al.  Influence of delayed viral production on viral dynamics in HIV-1 infected patients. , 1998, Mathematical biosciences.

[18]  C B Hall,et al.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection , 1988, Journal of virology.

[19]  Wenhui Li,et al.  Influenza A Virus Neuraminidase Limits Viral Superinfection , 2008, Journal of Virology.

[20]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[21]  A. Perelson,et al.  Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.